Please use this identifier to cite or link to this item: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3845
Journal Title: Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
Authors: Hailu, Kirubel
Cannon, Chad
Hayes, Sarah
Keywords: Brain Ischemia
Fibrinolytic Agents
Humans
Ischemic Stroke
Stroke
Tenecteplase
Tissue Plasminogen Activator
Treatment Outcome
Alteplase
Fibronlytics
Pharmacotherapy
Tenecteplase
Thrombolytics
Issue Date: Jun-2022
Date Accessioned: 2023-04-24T02:44:20Z
Date Available: 2023-04-24T02:44:20Z
Accession Number: 35020806
Url: https://www.ncbi.nlm.nih.gov/pubmed/35020806
Description Affiliation: Department of Pharmacy, Ascension St. Vincent's Riverside, Jacksonville, FL, USA.
Format Startpage: 944-949
Source Volume: 79
Issue Number: 12
Database: Medline
Notes: eng
Review
England
2022/01/13
DOI: 10.1093/ajhp/zxac010
Date: Jun 7
NLM
2022
Abstract: PURPOSE: Several research articles have been published within the last decade comparing the use of tenecteplase to alteplase in ischemic stroke management. Prior reporting on the comparative therapeutic efficacy and safety profiles of tenecteplase and alteplase is reviewed. SUMMARY: Tenecteplase is a variant of native tissue-type plasminogen activator, which rapidly promotes thrombolysis by catalyzing formation of the serine protease plasmin. Tenecteplase has theoretical advantages over alteplase as it has greater fibrin specificity and has a longer half-life than alteplase. This allows the administration of a single bolus over 5 to 10 seconds, as opposed to a bolus followed by a 1-hour infusion with alteplase. While currently approved by the Food and Drug Administration for the treatment of ST-segment elevation myocardial infarction, tenecteplase has also been studied in the treatment of acute ischemic stroke and has extensive data for this off-label indication. The most comprehensive trials to date evaluating the use of tenecteplase in acute ischemic stroke include the TNK-S2B, Australian TNK, ATTEST, Nor-Test, and EXTEND-IA TNK trials. Findings from these randomized controlled studies suggest that tenecteplase is at least as efficacious as alteplase in terms of neurological outcomes. The majority of these studies also reported a trend toward improved safety profiles with the use of tenecteplase. CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.
URI: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3845
Journal Title: American Journal of Health-System Pharmacy
Type: Journal Article
Appears in Collections:SWH Data Contributions

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing